Hyperlipidemia is a major risk factor for cardiovascular morbidity and mortality. Statins are
the first-choice therapy for dyslipidemias and are considered the cornerstone of …

Abstract The Proceedings of a Canadian Working Group Consensus Conference, first
published in 2011, provided a summary of statin-associated adverse effects and intolerance …

The clinical spectrum of muscle-and skeletal-related side-effects of statins includes varied
myalgias and weakness, an asymptomatic increase in the concentration of creatine kinase …

Hyperlipidaemia is a major risk factor for cardiovascular morbidity and mortality. 3‐hydroxy‐
3‐methylglutaryl coenzyme‐A reductase inhibitors ('statins') are first‐line therapies for …

Addressing the factors which lead to the development of statin-associated muscle symptoms
(SAMS) is vital for maintaining patient compliance with these pharmaceuticals, and thus …

A sensitive and specific method, utilising high performance liquid chromatography tandem
mass spectrometry (HPLC–MS/MS) was developed for the quantitative determination of …

Introduction: Statin therapy is the backbone of pharmacologic therapy for low-density
lipoproteins cholesterol lowering and plays a pivotal role in cardiovascular disease …

Purpose Current issues regarding biosimilar drug use are reviewed in a two-part article from
the perspective of pharmacy practice. Background Statins are known to be safe, but some …

We retrospectively studied 21 patients who had difficulty tolerating daily or alternating-day
statins. Patients received rosuvastatin at a mean frequency of 1.7 doses per week, and a …

Nondaily statin dosing: mechanisms of a potentially important approach to dealing with statin
intolerance. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …